Vasculitis - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 105 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Vasculitis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Vasculitis - Pipeline Review, H1 2015', provides an overview of the Vasculitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vasculitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vasculitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vasculitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Vasculitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Vasculitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Vasculitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Vasculitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Vasculitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction
Global Markets Direct Report Coverage
Vasculitis Overview
Therapeutics Development
Pipeline Products for Vasculitis - Overview
Pipeline Products for Vasculitis - Comparative Analysis
Vasculitis - Therapeutics under Development by Companies
Vasculitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Vasculitis - Products under Development by Companies
Vasculitis - Companies Involved in Therapeutics Development
AnGes MG, Inc.
Anthera Pharmaceuticals‚ Inc.
Aprogen, Inc.
ChemoCentryx, Inc.
Clearside BioMedical, Inc.
Epirus Biopharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Hemostemix Ltd
Hospira, Inc.
K-Stemcell Co., Ltd.
Panacea Biotec Limited
Pluristem Therapeutics Inc.
Sandoz Inc.
XOMA Corporation
Vasculitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACP-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
belimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
beperminogene perplasmid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
blisibimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CCX-168 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
gevokizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tocilizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
triamcinolone acetonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vascostem - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vasculitis - Recent Pipeline Updates
Vasculitis - Dormant Projects
Vasculitis - Product Development Milestones
Featured News & Press Releases
Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA
Apr 03, 2013: GlaxoSmithKline Starts Phase III Study Of Benlysta In Patients With Vasculitis
Jan 10, 2013: Clearside Biomedical Announces Plans For Clinical Testing Of CLS1001 Suprachoroidal Injectable Suspension For Treatment Of Some Eye Diseases
Aug 17, 2012: Anges Announces Publication Of Long-Term Phase I/II Trial Data Of Collategene In Medical Journal
Aug 16, 2012: Pluristem Receives Approval From Indian Ministry Of Health For Use Of PLX Cells In Phase II Trial For Treatment Of Buerger's Disease
May 26, 2012: ChemoCentryx Presents Data on CCX168 At 49th European Renal Association-European Dialysis And Transplant Association Congress
Oct 17, 2011: ChemoCentryx Initiates Phase II Clinical Trial For CCX168 In Vasculitis
Mar 24, 2011: AnGes Publishes Results Of Collategene Study In International Angiology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Vasculitis, H1 2015
Number of Products under Development for Vasculitis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Vasculitis - Pipeline by AnGes MG, Inc., H1 2015
Vasculitis - Pipeline by Anthera Pharmaceuticals‚ Inc., H1 2015
Vasculitis - Pipeline by Aprogen, Inc., H1 2015
Vasculitis - Pipeline by ChemoCentryx, Inc., H1 2015
Vasculitis - Pipeline by Clearside BioMedical, Inc., H1 2015
Vasculitis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015
Vasculitis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Vasculitis - Pipeline by GlaxoSmithKline plc, H1 2015
Vasculitis - Pipeline by Hemostemix Ltd, H1 2015
Vasculitis - Pipeline by Hospira, Inc., H1 2015
Vasculitis - Pipeline by K-Stemcell Co., Ltd., H1 2015
Vasculitis - Pipeline by Panacea Biotec Limited, H1 2015
Vasculitis - Pipeline by Pluristem Therapeutics Inc., H1 2015
Vasculitis - Pipeline by Sandoz Inc., H1 2015
Vasculitis - Pipeline by XOMA Corporation, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Vasculitis Therapeutics - Recent Pipeline Updates, H1 2015
Vasculitis - Dormant Projects, H1 2015